The sustainable success of the pharmaceuticals industry in Berlin-Brandenburg is based on a history of innovative products going back to the 19th century. Global players such as Bayer, Berlin-Chemie (Menarini), Pfizer, Sanofi, and Takeda as well as more than 20 pharmaceutical SMEs are based in Berlin-Brandenburg and employ around 11,000 people.
"Berlin is becoming more and more interesting as centre for innovation and we can act more confidently. Medicine and biotechnology are future fields which are worth investing in here. There are also great universities and successful biotech companies in other German cities. But in addition to the scientific environment, we are also home to some very large pharmaceutical companies such as Sanofi, Pfizer, Bayer, and Berlin-Chemie as well as many smaller start-ups."
Michael Müller, Governing Mayor of Berlin (Source: Der Tagesspiegel)
The industry benefits from
- an excellent scientific and clinical environment
- the biotech expertise in the region
- proximity to the decision-makers for the German healthcare system
- the central geographical location of the German capital region with good access to Western, Central, and Eastern European markets
- the close connection between research, development, and clinical practice
- well established translational research
- excellent infrastructure for technology transfer
- numerous options for clinical trials
With a large and diverse patient population and over 130 hospitals, the Berlin-Brandenburg region makes all types of clinical research projects possible.
„The Berlin-Brandenburg metropolitan area is a unique place inside the German healthcare sector. Nowhere else in Germany will you find a comparable concentration of world class science, hospitals and industry. This cross-functional cluster turns the German capital region into a true magnet for healthcare investments in Europe.“
Berlin has the most clinical trials in Germany (as of 2016). The driver is above all the Charité, Germany's largest and most renowned university hospital, and it subsidiary the Charité Research Organisation (CRO). Early clinical studies from first time in human (FTIH) testing to proof of concept (PoC) as well as complex clinical trials with a translational approach in many therapeutic areas are its main focus. Around 20 other clinical research organisations are located in the capital region (including Parexel).
|Global players||Successful medium-sized pharmaceutical companies|